Pacira BioSciences (PCRX)
(Real Time Quote from BATS)
$14.14 USD
-0.39 (-2.68%)
Updated Sep 23, 2024 11:46 AM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
PCRX 14.14 -0.39(-2.68%)
Will PCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCRX
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacira (PCRX) Down 27.9% Since Last Earnings Report: Can It Rebound?
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Other News for PCRX
Pacira BioSciences Inc (PCRX) Trading Down 3.65% on Sep 23
Pacira BioSciences Inc (PCRX) Shares Up 5.26% on Sep 16
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
Pharmacorp Rx Inc. Expands with New Pharmacy Acquisition